Difference between revisions of "Refametinib (BAY-869766)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/refametinib NCI Drug Dictionary]: An orally bioavailable selective MEK inhib...") |
Warner-admin (talk | contribs) m (Warner-admin moved page Refametinib (BAY 869766) to Refametinib (BAY-869766) without leaving a redirect) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
===[[Hepatocellular carcinoma]]=== | ===[[Hepatocellular carcinoma]]=== | ||
| − | # Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. Epub 2018 Jun 27. [http://clincancerres.aacrjournals.org/content/early/2018/08/08/1078-0432.CCR-17-3588 link to original article] [https:// | + | # Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. Epub 2018 Jun 27. [http://clincancerres.aacrjournals.org/content/early/2018/08/08/1078-0432.CCR-17-3588 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29950351/ PubMed] |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' BAY-869766 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:MAP2K1 inhibitors]] | [[Category:MAP2K1 inhibitors]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 12:43, 27 July 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation.
Preliminary data
Hepatocellular carcinoma
- Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. Epub 2018 Jun 27. link to original article PubMed
Also known as
- Code name: BAY-869766